|
Congenital Abnormality
|
0.010 |
GeneticVariation
|
group |
BEFREE |
ARID1B gene mutations have been associated with two hereditary syndromic conditions, namely Coffin-Siris (CSS, MIM#135900) and Nicolaides-Baraitser syndromes (NCBRS, MIM#601358), characterized by neurodevelopment delay, craniofacial dysmorphisms and skeletal anomalies.
|
31421289 |
2020 |
|
Congestive heart failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present study was a subanalysis of the BRIGHT-D study that focused on the effects of bisoprolol vs carvedilol on inflammation and oxidative stress in CHF patients.
|
31444140 |
2020 |
|
Hypoglycemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Use of Gla-300 resulted in similar glycaemic control as IDeg-100 during the initial 12-week titration period of the BRIGHT study, when less anytime (24 h) hypoglycaemia with Gla-300 vs IDeg-100 has been reported.
|
31646724 |
2020 |
|
Subcutaneous panniculitis-like T-cell lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Variants of interest identified include 1 missense mutation in ARID1B in 1 case of SPTCL.
|
31702703 |
2020 |
|
Abnormality of the skeletal system
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
ARID1B gene mutations have been associated with two hereditary syndromic conditions, namely Coffin-Siris (CSS, MIM#135900) and Nicolaides-Baraitser syndromes (NCBRS, MIM#601358), characterized by neurodevelopment delay, craniofacial dysmorphisms and skeletal anomalies.
|
31421289 |
2020 |
|
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
These findings open up perspectives for targeting ARID1B in combination with radiotherapy to improve outcomes of patients with ARID1A-mutant CRC.
|
31796878 |
2019 |
|
Tuberculosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Relative to all laboratory-diagnosed TB, the diagnostic yields of sputum GeneXpert (1 sample per subject) and OSA (2 samples per subject) were identical at 49/59 (83.1%) each.The specificity of the OSA was 91.5%.
|
30541931 |
2019 |
|
Tuberous Sclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A young woman with NDD due to a de novo mutation in ARID1B now presented with a large renal (> 19 cm in diameter) and multiple hepatic angiomyolipomas (AMLs) but no other signs of tuberous sclerosis complex.
|
31077186 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interactions of cg14146378-hsa-mir-205-ARID1B and cg15375596-has-miR-1275-IGF1R may be used as the prognosis indicators in lung adenocarcinoma.
|
30868896 |
2019 |
|
Angiomyolipoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A young woman with NDD due to a de novo mutation in ARID1B now presented with a large renal (> 19 cm in diameter) and multiple hepatic angiomyolipomas (AMLs) but no other signs of tuberous sclerosis complex.
|
31077186 |
2019 |
|
Congenital malformation of corpus callosum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that corpus callosum anomalies caused in ARID1B mutations may be predictive of the visuospatial and motor phenotype in Coffin-Siris syndrome.
|
30933046 |
2019 |
|
Sleep Apnea, Obstructive
|
0.010 |
Biomarker
|
disease |
BEFREE |
The stage of OSA severity was set according to the following criteria of the apnea-hypopnea index (AHI): AHI < 5/h - no disease (OSA-0; n = 26), AHI 5-15/h - mild disease (OSA-1; n = 26), AHI 16-30/h - moderate disease (OSA-2: n = 27), and AHI > 30/h obstructive episodes per hour - severe disease (OSA-3; n = 27).
|
31559568 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ARID1B expression was associated with lymph node metastasis status, histological grade and p53 expression.
|
30867762 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study indicate that significant association exists between the nuclear expression of ARID1B and adverse prognosis in TNBC.
|
30867762 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
|
31796878 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study indicate that significant association exists between the nuclear expression of ARID1B and adverse prognosis in TNBC.
|
30867762 |
2019 |
|
Anaplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma.
|
28863077 |
2018 |
|
Undifferentiated carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Ten of the remaining 17 undifferentiated carcinomas showed the following alterations: 5 tumors (15%) showed loss of ARID1A only with intact ARID1B, BRG1, and INI1 expression, 4 tumors (12%) showed mutated patterns of p53 staining with intact SWI/SNF protein expression, and 1 tumor (3%) harbored a POLE exonuclease domain mutation (P286R).
|
28863077 |
2018 |
|
Endometrial Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We recently identified 3 mutually exclusive mechanisms of switch/sucrose nonfermentable (SWI/SNF) complex inactivation (BRG1 inactivation, INI1 inactivation or ARID1A/ARID1B co-inactivation) that are associated with histologic dedifferentiation in the majority of dedifferentiated endometrial carcinoma.
|
28863077 |
2018 |
|
Secondary malignant neoplasm of liver
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Epigenetic regulators including KMT2C/MLL3 and ARID1B, which are mutated in >50% of hepatocellular carcinomas, were also mutated in liver metastases.
|
28892047 |
2018 |
|
Ovarian clear cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
|
29890703 |
2018 |
|
Achondroplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Six patients with achondroplasia underwent midface advancement for treatment of OSA (2 LF2 + LF1/BSSO, 2 LF2, 2 LF3).
|
29108917 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed to determine the association between ARID1B expression and outcomes, as well as the benefit from adjuvant chemotherapy in patients with bladder cancer.
|
29151933 |
2017 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed to determine the association between ARID1B expression and outcomes, as well as the benefit from adjuvant chemotherapy in patients with bladder cancer.
|
29151933 |
2017 |
|
Developmental Disabilities
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Further studies are needed to determine the detailed molecular and cellular mechanisms by which constitutional haploinsufficiency of ARID1B causes syndromic and non-syndromic developmental disabilities.
|
28691782 |
2017 |